Osteonecrosis Clinical Trial
Official title:
Functional Outcomes for Children, Adolescents, and Young Adults With Osteonecrosis Following Hip Core Decompression
NCT number | NCT02458937 |
Other study ID # | ONFUNC |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 5, 2015 |
Est. completion date | September 26, 2018 |
Verified date | November 2018 |
Source | St. Jude Children's Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Although uncommon in the general pediatric population, osteonecrosis (ON) is prevalent in
children and adolescents with cancer, particularly among those that have had chronic exposure
to glucocorticoids and among those having undergone allogeneic hematopoietic stem cell
transplantation. Patients with hematologic disease are also at risk for developing ON.
Hip Core Decompression (HCD) is a widely used surgical procedure with several studies
reporting positive results; however, most are subject to criticism because of the limited
sample size or the absence of appropriate functional outcome measures.
The objective of this pilot study is to observe and collect information on several functional
outcome measures and assess if Hip Core Decompression (HCD) potentially improves functional
outcomes in children, adolescents and young adults with osteonecrosis.
PRIMARY OBJECTIVE:
- To describe functional outcomes of children, adolescents, and young adults with
osteonecrosis of the femoral head following hip core decompression surgery. Parameters
assessed will include pain, functional mobility, endurance, quality of life, and gait
patterns pre-operatively and post-operatively over time.
Status | Completed |
Enrollment | 17 |
Est. completion date | September 26, 2018 |
Est. primary completion date | September 26, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 29 Years |
Eligibility |
Inclusion Criteria: - Patient being treated at St. Jude Children's Research Hospital - Diagnosis of osteonecrosis of the hip - Diagnosis of hematologic malignancy or sickle cell disease - Age between 8 and 29 years of age - Patient and/or parent or legal guardian must sign a written informed consent - Patient is considered an acceptable candidate for hip core decompression surgery by his/her primary physician and orthopedic surgeon Exclusion Criteria: - Patient with a diagnosis that is not a hematologic malignancy or sickle cell disease - Patient that has had amputation or reconstructive surgery of the lower extremities - Premorbid condition that prevents patient from ambulating - Patient that has a serious, non-healing wound, ulcer, or bone fracture |
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | Tennessee Physical Therapy Association |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Degree of Pain | Pain is measured by using a numeric scale requiring patients to rate any pain experienced in the prior week on a 0 (no pain) to 10 (worst pain imaginable) scale | At 1 year after surgery | |
Primary | Functional Mobility | Functional mobility will be measured by using the Timed Up and Down Stairs (TUDS) and Timed Up and Go (TUG). TUDS assesses the time required for a patient to walk up and down 12 stairs to measure functional mobility, balance, and motor skills. TUG measures the time needed to stand from a seated position, ambulate 3 meters, turn around, return to chair and resume sitting. This will provide a measure of dynamic balance and mobility. | At 1 year after surgery | |
Primary | Physiological Cost Index (PCI) | Endurance will be assessed following completion of the 9-Minute Run-Walk Test. The patient will be instructed to walk or run for 9 minutes while trying to cover as much distance as possible. Heart rate (HR) and rate of perceived exertion (RPE) data will be collected during the walk/run. RPE measures the level of the patient's exertion using a likert scale of numbers (6-20) and adjectives describing effort. A wheeled feet counter will measure distance and a stopwatch will track time. Upon completion of the 9-minute run-walk, the physiological cost index (PCI) will be calculated by dividing the difference in the patient's heart rate (HR while walking- HR at rest) by walking speed in meters per minute. | At 1 year after surgery | |
Primary | Quality of Life | The use of supports, patient satisfaction, and participation in the community will be measured by patient provided responses to questions pertaining to the use of supports (brace, cane, crutches), satisfaction with walking quality, and participation in school, work, and/or sports. The responses will be scored on a 0-5 scale, with 0 demonstrating the least preferred outcome. | At 1 year after surgery | |
Primary | Temporo-Spatial Gait Parameters | Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator. | At 1 year after surgery | |
Primary | Range of Motion | Active and passive ROM will be measured using a goniometer. Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. ROM will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. | At 1 year after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04072055 -
MOTO Post-marketing Surveillance Study
|
||
Terminated |
NCT02941666 -
Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip
|
||
Terminated |
NCT01763684 -
Oxford Signature vs. Conventional Global Study
|
N/A | |
Completed |
NCT00505219 -
Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head
|
Phase 3 | |
Withdrawn |
NCT02632903 -
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
|
Phase 2 | |
Active, not recruiting |
NCT01458782 -
ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee
|
N/A | |
Completed |
NCT01583465 -
Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty
|
N/A | |
Active, not recruiting |
NCT04401267 -
Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
|
Phase 2 | |
Completed |
NCT03197623 -
Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids
|
Phase 1 | |
Active, not recruiting |
NCT05283148 -
Sickle Cell Disease (SCD) Bone Pain Study
|
N/A | |
Completed |
NCT05684588 -
Post-COVID-19 Sequelae: Osteonecrosis of Femoral Head
|
N/A | |
Terminated |
NCT03269409 -
Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis
|
Phase 1 | |
Completed |
NCT00913679 -
A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty
|
N/A | |
Enrolling by invitation |
NCT02893293 -
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
|
Phase 4 | |
Completed |
NCT01345097 -
A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients
|
Phase 4 | |
Recruiting |
NCT00260897 -
Molecular Genetic Study of Avascular Necrosis of the Femoral Head
|
N/A | |
Not yet recruiting |
NCT06016634 -
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
|
Phase 2 | |
Completed |
NCT02077647 -
Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee
|
||
Recruiting |
NCT01619124 -
Osteonecroses in Pediatric Patients With ALL
|
N/A | |
Recruiting |
NCT02661139 -
Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction
|